Navigation Links
Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
Date:5/23/2012

WEST ORANGE, N.J., May 23, 2012 /PRNewswire/ -- Everett Laboratories, Inc., Women's Health Care company, leader in the field of prenatal supplementation, today announced that it had filed a patent infringement lawsuit with a motion for a preliminary injunction in the United States District Court of New Jersey against Trigen Laboratories, Inc., a specialty niche pharmaceutical company.  The lawsuit asserts, among other things, that Trigen is infringing United States Patent No. 8,183,227 covering Everett's Vitafol®-One product, and seeks to prevent Trigen from making, selling, distributing and falsely branding its infringing, copycat products.  Everett's lawsuit alleges that it will be irreparably harmed unless the court issues a preliminary injunction that requires Trigen immediately to withdraw its patent-infringing products from the market.    

"We are fully committed to our innovation and to providing physicians and their patients with quality products for prenatal supplementation," said Lucas Sigman, Everett's Chief Executive Officer.  "Our prenatal supplementation portfolio represents one of the Company's most valuable assets, and provides significant market and competitive advantages.  We will not tolerate infringement of our patents, and we will do what is necessary to protect our proprietary rights."

Everett's lawsuit also alleges that Trigen's copycat products contain fish oil while Everett DHA is made from Algae oil.  "We are committed to providing pregnant women with the highest-quality prenatal supplementation.  That is our number one priority," said Louis Bongiovanni, Everett's Vice President of Sales. 

About Everett Laboratories, Inc.

Everett Laboratories is a New Jersey-based women's healthcare pharmaceutical company that has been providing essential pharmaceutical and nutritional products for four decades.  Everett is a subsidiary of The Chemo Group, a global healthcare corporation based in Spain with a presence in more than 30 countries.  The company recently licensed products for stress urinary incontinence, fertility, and the Stuart Natal line of pre-natal vitamins.  Everett is dedicated to providing advanced treatments and innovative new products to address unmet needs for women and families and to improving women's health.  The company strives to produce and market unique, first-in-class prescription and over the counter medications.


'/>"/>
SOURCE Everett Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Colonel (Ret) Everett McAllister Named as New PTCB Executive Director and Chief Executive Officer
2. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
3. The Law Firm of Levi & Korsinsky Launches an Investigation Into Possible Breaches of Fiduciary Duties and Unjust Enrichment by the Board of Directors of Abbott Laboratories, Inc.
4. Unity Management Group Receives Large Purchase Order for their AIM Instrumentation Package From Barr Laboratories, Subdivision of TEVA Pharmaceuticals (NASDAQ: TEVA)
5. Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc.
6. MO BIO Laboratories, Inc. Launches the PowerWater® Sterivex™ DNA Isolation Kit
7. ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC
8. Announcement - Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System
9. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011
10. Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities
11. Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Pharmacy, Inc. (NYSE: DPLO) has been recognized by the Detroit ... Standard. To learn more about Diplomat,s career opportunities, visit ... ... ... LLC, a research firm specializing in organizational health and workplace improvement. ...
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has ... and Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Electrodes Market is poised to grow at a CAGR of around ... the market is witnessing include advancements in extracellular microelectrode arrays and ...
Breaking Medicine Technology:
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development continuity to its innovative Unified Instance Manager architecture, meeting the needs ... this new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
Breaking Medicine News(10 mins):